Company news

Jazz Pharmaceuticals plc news in 2020

Jazz Pharmaceuticals plc's news releases, calls and decks from 2020, newest first.

View company

Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

December 20, 2020

Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line

December 2, 2020

Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors

November 16, 2020

Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference

November 9, 2020

Jazz Pharmaceuticals Announces Third Quarter 2020 Financial Results

November 1, 2020

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program

October 25, 2020

Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy

October 19, 2020

Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update

October 18, 2020

Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia

October 7, 2020

Jazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of Leukemia

September 16, 2020

Jazz Pharmaceuticals Announces New Sleep Health Collaboration

September 14, 2020

Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies

September 8, 2020

Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results

August 3, 2020

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

July 21, 2020

Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020

July 20, 2020

Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer

June 14, 2020

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026

June 8, 2020

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026

June 7, 2020

Jazz Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

May 26, 2020

Jazz Pharmaceuticals Announces Appointment Of Kim Sablich As Executive Vice President, General Manager Of North America

May 10, 2020

Jazz Pharmaceuticals Announces Participation at Upcoming Virtual Investor Conferences

May 5, 2020

Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results

May 4, 2020

Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease

April 28, 2020

Jazz Pharmaceuticals to Report 2020 First Quarter Financial Results on May 5, 2020

April 20, 2020

Jazz Pharmaceuticals Provides COVID-19 Business Update

March 30, 2020

Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

March 24, 2020

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2019 Financial Results

February 24, 2020

Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020

February 10, 2020

Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

January 21, 2020

Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

January 19, 2020

Decks in 2020